Key facts
- SonarMD’s last known valuation is $18.1M (Mar 2026).
- It has raised $23.0M across 4 recorded rounds; the latest was Seed Round ($3.0M) in Feb 2026.
- Notable investors include Matter (Consulting Services (B2B)), Arboretum Ventures, Nueterra Capital, Blue Hour Ventures, Blue Venture Fund — 7 tracked in total.
- SonarMD has filed 4 Form Ds with the SEC since 2020, most recently Jan 2025 ($2.2M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for SonarMD
Funding rounds
4 roundsAbout SonarMD
Provider of care coordination and therapeutic optimization services intended for carrying out treatment of complex chronic conditions that use drugs. The company's services involve rendering care management which enhances patient engagement, and care coordination and utilizes specialty pharmacy optimization, enabling clients to improve the experience of health services for both patients and clinical teams.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2015
- Employees
- 20
- Website
- sonarmd.com/
- Ownership
- Privately Held (backing)
SonarMD doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SonarMD shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SonarMD in its N-PORT filings yet. We sweep new filings monthly.